MA38949A1 - Forme saline d'hydrochlorure pour inhibition d'ezh2 - Google Patents

Forme saline d'hydrochlorure pour inhibition d'ezh2

Info

Publication number
MA38949A1
MA38949A1 MA38949A MA38949A MA38949A1 MA 38949 A1 MA38949 A1 MA 38949A1 MA 38949 A MA38949 A MA 38949A MA 38949 A MA38949 A MA 38949A MA 38949 A1 MA38949 A1 MA 38949A1
Authority
MA
Morocco
Prior art keywords
dgat1
ezh2
hydrochloride
inhibition
saline form
Prior art date
Application number
MA38949A
Other languages
English (en)
Inventor
Kevin W Kuntz
Hyeong-Wook Choi
Steven Mathieu
Kristen Sanders
Arani Chanda
Original Assignee
Eisai R&D Man Co Ltd
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd, Epizyme Inc filed Critical Eisai R&D Man Co Ltd
Publication of MA38949A1 publication Critical patent/MA38949A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux composés qui sont des inhibiteurs d'acyl-coenzyme a: diacylglycérol transférase 1 (dgat1), des compositions pharmaceutiques les contenant, des procédés pour leur préparation, ainsi que leur utilisation en thérapie, seuls ou en combinaison avec des thérapies de gestion du poids ou autre thérapie de diminution des triglycérides pour la prévention ou le traitement de maladies liées à un dysfonctionnement de dgat1 ou dans lesquelles une modulation de l'activité de dgat1 peut avoir un bénéfice thérapeutique.
MA38949A 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2 MA38949A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361891786P 2013-10-16 2013-10-16
PCT/US2014/060724 WO2015057859A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Publications (1)

Publication Number Publication Date
MA38949A1 true MA38949A1 (fr) 2017-07-31

Family

ID=52828660

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38949A MA38949A1 (fr) 2013-10-16 2014-10-15 Forme saline d'hydrochlorure pour inhibition d'ezh2

Country Status (24)

Country Link
US (3) US10040782B2 (fr)
EP (2) EP4324525A2 (fr)
JP (2) JP6608812B2 (fr)
KR (1) KR102142177B1 (fr)
CN (1) CN105829302B (fr)
AU (2) AU2014337300B2 (fr)
CA (1) CA2925889C (fr)
CL (1) CL2016000866A1 (fr)
DK (1) DK3057962T3 (fr)
EA (1) EA038869B1 (fr)
ES (1) ES2960953T3 (fr)
FI (1) FI3057962T3 (fr)
HU (1) HUE063984T2 (fr)
IL (1) IL244787B (fr)
LT (1) LT3057962T (fr)
MA (1) MA38949A1 (fr)
MX (1) MX2016004703A (fr)
MY (1) MY179802A (fr)
PE (1) PE20161273A1 (fr)
PL (1) PL3057962T3 (fr)
PT (1) PT3057962T (fr)
SG (2) SG10201901977XA (fr)
SI (1) SI3057962T1 (fr)
WO (1) WO2015057859A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2836491T (pt) 2012-04-13 2017-02-08 Eisai R&D Man Co Ltd Forma salina de um inibidor da histona metiltransferase humana ezh2
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
US20160303135A1 (en) 2013-12-06 2016-10-20 Epizyme, Inc. Combination therapy for treating cancer
US10166238B2 (en) 2014-06-17 2019-01-01 Epizyme, Inc. EZH2 inhibitors for treating lymphoma
EP3206688A4 (fr) 2014-10-16 2018-06-13 Epizyme, Inc. Méthode de traitement du cancer
US10786511B2 (en) * 2014-11-17 2020-09-29 Epizyme, Inc. Method for treating cancer
CA2983265A1 (fr) 2015-04-20 2016-10-27 Health Research, Inc. Polytherapie pour le traitement du cancer
JP6890097B2 (ja) 2015-06-10 2021-06-18 エピザイム，インコーポレイティド リンパ腫を処置するためのｅｚｈ２阻害剤
AU2016312514A1 (en) 2015-08-24 2018-03-15 Epizyme, Inc. Method for treating cancer
WO2017132518A1 (fr) 2016-01-29 2017-08-03 Epizyme, Inc. Polythérapie pour le traitement du cancer
EP3464643A4 (fr) 2016-06-01 2020-04-01 Epizyme Inc Utilisation d'inhibiteurs de ezh2 pour le traitement du cancer
WO2017218953A1 (fr) 2016-06-17 2017-12-21 Epizyme, Inc. Inhibiteurs d'ezh2 pour traiter le cancer
CN110191722B (zh) 2017-01-19 2022-03-01 第一三共株式会社 用于治疗htlv-1相关性脊髓病的药物组合物
WO2018183885A1 (fr) 2017-03-31 2018-10-04 Epizyme, Inc. Multithérapie pour le traitement du cancer
AU2018275123A1 (en) 2017-06-02 2020-01-30 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CA3074720A1 (fr) 2017-09-05 2019-03-14 Epizyme, Inc. Polytherapie pour le traitement du cancer
JP2021531340A (ja) 2018-07-09 2021-11-18 フォンダシヨン、アジール、デ、アブグルスFondation Asile Des Aveugles 眼障害を治療するためのｐｒｃ２サブユニットの阻害
US20220298222A1 (en) 2019-08-22 2022-09-22 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
WO2000018725A1 (fr) 1998-09-30 2000-04-06 The Procter & Gamble Company Cetoamides 2-substitues
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
ES2330719T3 (es) 2000-12-28 2009-12-15 SHIONOGI & CO., LTD. Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2.
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
EP2130820A1 (fr) 2002-02-19 2009-12-09 Shionogi & Co., Ltd. Antiprurigineux
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
BRPI0618417A2 (pt) 2005-10-19 2012-07-31 Gruenenthal Chemie novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
EP1951672B1 (fr) 2005-10-21 2011-05-25 Merck Sharp & Dohme Corp. Inhibiteurs du canal potassique
JP5078901B2 (ja) 2005-10-28 2012-11-21 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ＪｍｊＣドメインを含むタンパク質デメチラーゼ
WO2007070818A1 (fr) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Heterocycles a six elements utiles en tant qu’inhibiteurs de serine protease
US8524467B2 (en) 2006-01-20 2013-09-03 The University Of North Carolina At Chapel Hill Diagnostic and therapeutic targets for leukemia
EP2018166A2 (fr) 2006-05-15 2009-01-28 Irm Llc Composés et compositions de téréphtalamate, et leur utilisation en tant qu'inhibiteurs de l'intégrase du vih
CA2652634A1 (fr) 2006-05-18 2007-11-29 Amphora Discovery Corporation Certaines quinolones substituees, compositions et utilisations
CA2666461A1 (fr) 2006-10-10 2008-09-12 Burnham Institute For Medical Research Compositions neuroprotectrices et procedes correspondants
US8314087B2 (en) 2007-02-16 2012-11-20 Amgen Inc. Nitrogen-containing heterocyclyl ketones and methods of use
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
WO2008113006A1 (fr) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (fr) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions et méthodes pour inhiber la protéine ezh2
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
CA2709257C (fr) 2007-12-19 2016-12-13 Cancer Research Technology Limited Composes pyrido[2,3-b]pyrazine substitues en position 8 et leur utilisation
WO2009124137A2 (fr) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Procédé de suppression d’une transcription de gène par méthylation d’histone lysine
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
JP5548197B2 (ja) 2008-08-08 2014-07-16 ニューヨーク ブラッド センター， インコーポレイテッド レトロウイルスの集合及び成熟の小分子阻害剤
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
US20120065247A1 (en) 2009-03-27 2012-03-15 Discoverybiomed, Inc. Modulating ires-mediated translation
US20110021362A1 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (fr) 2009-12-30 2011-07-07 Avon Products, Inc. Composition eclaircissante topique et utilisations de celle-ci
EA023788B1 (ru) 2010-05-07 2016-07-29 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Производные индола и фармацевтические композиции на их основе
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
WO2011140325A1 (fr) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
CN103261890B (zh) 2010-09-10 2016-04-06 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2607064T3 (es) 2010-12-01 2017-03-29 Glaxosmithkline Llc Indoles
WO2012075500A2 (fr) 2010-12-03 2012-06-07 Epizyme, Inc. Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci
EP2681216B1 (fr) 2011-02-28 2017-09-27 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
CN110420327B (zh) 2012-03-12 2022-05-03 Epizyme股份有限公司 人ezh2抑制剂及其应用方法
PT2836491T (pt) 2012-04-13 2017-02-08 Eisai R&D Man Co Ltd Forma salina de um inibidor da histona metiltransferase humana ezh2
ES2925312T3 (es) 2012-04-13 2022-10-14 Epizyme Inc Terapia combinada para el tratamiento del cáncer
WO2013173441A2 (fr) 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
CA3177498A1 (fr) 2012-10-15 2014-04-24 Epizyme, Inc. Methodes de traitement du cancer
SG11201502803VA (en) 2012-10-15 2015-05-28 Epizyme Inc Substituted benzene compounds
AU2013361060B2 (en) 2012-12-21 2018-04-19 Epizyme, Inc. 1,4-pyridone compounds
EP2935264B1 (fr) 2012-12-21 2017-10-18 Epizyme, Inc. Composés hétéroaryles bicycliques 1,4-pyridone
WO2014144747A1 (fr) 2013-03-15 2014-09-18 Epizyme, Inc. Composés hétéroaryles bicycliques substitués condensés en 6,5
WO2014172044A1 (fr) 2013-03-15 2014-10-23 Epizyme, Inc. Composés de benzène substitués
US9624205B2 (en) 2013-07-19 2017-04-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP3022184B1 (fr) 2013-07-19 2017-09-27 Epizyme, Inc. Composés de benzène substitués
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태

Also Published As

Publication number Publication date
CL2016000866A1 (es) 2016-12-23
SG10201901977XA (en) 2019-04-29
EP3057962A1 (fr) 2016-08-24
AU2014337300A1 (en) 2016-04-14
SG11201602269QA (en) 2016-04-28
EP4324525A2 (fr) 2024-02-21
CN105829302B (zh) 2020-09-08
PL3057962T3 (pl) 2024-01-29
US20210017163A1 (en) 2021-01-21
SI3057962T1 (sl) 2024-01-31
NZ718201A (en) 2021-09-24
AU2019202246A1 (en) 2019-04-18
FI3057962T3 (fi) 2023-11-03
DK3057962T3 (da) 2023-11-06
IL244787B (en) 2022-04-01
JP2019052181A (ja) 2019-04-04
CA2925889C (fr) 2020-09-29
ES2960953T3 (es) 2024-03-07
KR20160082993A (ko) 2016-07-11
US10040782B2 (en) 2018-08-07
EA038869B1 (ru) 2021-10-29
WO2015057859A1 (fr) 2015-04-23
EP3057962B1 (fr) 2023-10-18
CN105829302A (zh) 2016-08-03
AU2014337300B2 (en) 2019-01-03
MY179802A (en) 2020-11-16
KR102142177B1 (ko) 2020-08-07
PE20161273A1 (es) 2016-12-18
IL244787A0 (en) 2016-04-21
PT3057962T (pt) 2023-11-07
US20160237068A1 (en) 2016-08-18
JP6608812B2 (ja) 2019-11-20
US10710987B2 (en) 2020-07-14
US20180282312A1 (en) 2018-10-04
CA2925889A1 (fr) 2015-04-23
EA201690650A1 (ru) 2016-10-31
MX2016004703A (es) 2017-02-28
LT3057962T (lt) 2023-12-11
EP3057962A4 (fr) 2017-05-24
JP2016533349A (ja) 2016-10-27
HUE063984T2 (hu) 2024-02-28

Similar Documents

Publication Publication Date Title
MA38949A1 (fr) Forme saline d'hydrochlorure pour inhibition d'ezh2
MA45985B1 (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
MA40290A1 (fr) Agents immunorégulateurs
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX364378B (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA35945B1 (fr) Inhibiteurs de la bêta-sécrétase
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA38253A1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA49839B1 (fr) Inhibiteurs bicycliques de la histone déacétylase
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MX2016010892A (es) Agente para suprimir el progreso de o para mejorar la enfermedad renal cronica.
UA109359C2 (xx) Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
MA38102A1 (fr) Nouveaux composés utilisés comme inhibiteurs de diacylglycérol acyltransférase
PH12015501109A1 (en) Novel compounds as diacylglycerol acyltransferase inhibitors
MA45990B1 (fr) Combinaison d'agonistes inverses du récepteur de l'histamine-3 avec des inhibiteurs de l'acétylcholinestérase
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales